Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427931 · ClinicalTrials.gov registry record · NA
CGM Use in Islet Transplant Recipients
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03427931: Completed NA study, sponsored by University of Virginia.
NCT03427931 is a NA study that has completed, run by University of Virginia. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03427931, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
A study assessing glucose variability in subjects with Type 1 Diabetes who have had islet transplant.
Primary Outcome
Descriptive analysis for CGM use measuring percentage time in range of glucose between 70-180 mg/dL
Interventions
- OTHER Continuous Glucose Monitor (CGM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2019-07-11 |
| Phase | NA |
What the finished NCT03427931 record still lists
NCT03427931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitor (CGM) is the first listed.
NCT03427931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03427931 about?
NCT03427931 is a clinical study titled "CGM Use in Islet Transplant Recipients". A study assessing glucose variability in subjects with Type 1 Diabetes who have had islet transplant.
What is the current status of trial NCT03427931?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2018-02-01. Estimated completion is 2019-07-11.
What interventions are being tested in trial NCT03427931?
The interventions under investigation include: Continuous Glucose Monitor (CGM) (OTHER).
Who is sponsoring clinical trial NCT03427931?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03427931's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI